Cell Engineering Service
Cell engineering and genetic engineering together represent the latest development frontier of biotechnology and play an increasingly important role in the field of biopharmaceuticals. At our company, we recognize the transformative potential of cell engineering. By altering cells at the molecular level, we propel the development of effective treatments, biotechnological tools, and medical advancements. We offer a full suite of cell engineering services to support your research and development of rare disease therapies.
Introduction to Cell Engineering
Cell Engineering, an avant-grade field of study in biological sciences, employs the principles of biology and engineering to manipulate living cells' properties. This innovative and multi-disciplinary realm essentially modifies cellular components to elicit specific functions or traits necessary for translational research, biopharmaceuticals, or clinical applications. Cell engineering involves a wide range of fields. According to technical classification, it roughly includes cell fusion technology, cell disassembly technology, chromosome technology, gene transfer technology, embryo transplantation technology, and cell tissue culture technology. According to different cell types, cell engineering can be divided into plant and animal cell engineering.
Cell Engineering for Rare Diseases
Cell engineering plays a seminal role in combating rare and genetic diseases. Standard medical procedures often leave such pathologies neglected due to their rarity and the vast heterogeneity among patients. Cell engineering acts as a beacon of hope in this domain, providing ground-breaking and tailored therapies. From the intimate study of patient-specific iPSCs (induced pluripotent stem cells) to the more recent breakthroughs in CRISPR-Cas9 gene editing technology, the scope of cell engineering in the treatment of rare diseases is expansive.
Table 1 Advances in engineering cells for rare disease diagnosis. (Zhao, Ninglin, et al., 2023)
Rare Disease | Biomarker | Reporter | Diagnostics feature |
---|---|---|---|
Diabetes | Glucose | Fluorescence | Glucose-responsive integrase expression cassette (PCpxP-integrase-pA) that expresses the green fluorescent protein (GFP) for glycosuria testing. |
Vibrio cholera infection | Cholera autoinducer 1 (CAI-1) | Colorimetric enzymatic reaction | CqsS-NisK quorum sensing block for cholera autoinducer 1 (CAI-1) detection. |
Our Services
Through years of service and extensive expertise, our company is committed to the construction of cell engineering platforms and provides you with customized cell engineering services to deliver general cell lines and induced pluripotent stem cells (iPSCs) used for rare disease preclinical studies. We offer strict quality control and competitive prices and deliver cell products in a short time.
- Workflow of Cell Construction
Gene Editing
-Knock-ins (KI)
-Gene knockouts (KO)
-Point mutations (PM)
-Overexpression (OE)
Cell Transfection
-Standard (lipid/nanoparticle)
-Electroporation
-Transposon
-Viral vector
-mediated transduction
Cell Screening
-Flow cytometry
-Western blot
-PA-HPLC
-ELISA
-ClonePix
Cell Validation
-Thaw test
-Mycoplasma
-Clonal stability
-Receptor density estimation
- Target Types
Providing a variety of cell targeting services to achieve precise cell targeting.
- Enzymes
- Antibodies
- Membrane/structural proteins
- Reporter proteins
- Types of Cells
Optional cell types include, but are not limited to:
Why Choose Us?
As an integrated CRO, our company has the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease research projects. We provide comprehensive cell engineering services to leading and emerging biopharmaceutical companies and scientific research institutions. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Liang, Kaini, and Yanan Du. "Cell engineering techniques improve pharmacology of cellular therapeutics." Biomaterials and Biosystems 2 (2021): 100016.
- Zhao, Ninglin, et al. "Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development." Signal Transduction and Targeted Therapy 8.1 (2023): 112.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.